APO Research
Talk to an analyst

APO RESEARCH · REPORT

Drugs for Vulvovaginal Candidiasis

The cell wall of Candida is a complex glycoprotein that depends on the biosynthesis of ergosterol. Azole compounds, found in antimycotic drugs, are believed to block ergosterol production, allowing topical antimycotics to achieve cure rates in excess of 80%. The only oral azole agent approved for this indication by the US Food and Drug Administration (FDA) is fluconazole, which also achieves a high cure rate. Therapeutic concentrations are found in vaginal secretions for at least 72 hours after the ingestion of a single 150-mg tablet.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

The cell wall of Candida is a complex glycoprotein that depends on the biosynthesis of ergosterol. Azole compounds, found in antimycotic drugs, are believed to block ergosterol production, allowing topical antimycotics to achieve cure rates in excess of 80%. The only oral azole agent approved for this indication by the US Food and Drug Administration (FDA) is fluconazole, which also achieves a high cure rate. Therapeutic concentrations are found in vaginal secretions for at least 72 hours after the ingestion of a single 150-mg tablet.

Some women with recurrent candidal infections opt for treatment with over-the-counter (OTC) medications, which generally are highly effective for candidiasis. Preparations for intravaginal administration of butoconazole, clotrimazole, miconazole, and tioconazole are available OTC.

Selected research

Market Structure

Global Drugs for Vulvovaginal Candidiasis Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

25 December 2025190 pages

Choose your research edition.

Industry ResearchDrugs for Vulvovaginal Candidiasis Industry Research Report 2026120 pages · $2,950 USDIndustry Growth & TrendsGlobal Drugs for Vulvovaginal Candidiasis Industry Growth and Trends Forecast to 2032107 pages · $3,450 USDMarket StructureGlobal Drugs for Vulvovaginal Candidiasis Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Drugs for Vulvovaginal Candidiasis Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal Drugs for Vulvovaginal Candidiasis Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The cell wall of Candida is a complex glycoprotein that depends on the biosynthesis of ergosterol. Azole compounds, found in antimycotic drugs, are believed to block ergosterol production, allowing topical antimycotics to achieve cure rates in excess of 80%. The only oral azole agent approved for this indication by the US Food and Drug Administration (FDA) is fluconazole, which also achieves a high cure rate. Therapeutic concentrations are found in vaginal secretions for at least 72 hours after the ingestion of a single 150-mg tablet.

Some women with recurrent candidal infections opt for treatment with over-the-counter (OTC) medications, which generally are highly effective for candidiasis. Preparations for intravaginal administration of butoconazole, clotrimazole, miconazole, and tioconazole are available OTC.

The main manufacturers of Drugs for Vulvovaginal Candidiasis are Bayer, J & J, Pfizer, Perrigo, Effik, etc. The top three manufacturers in the world occupy about 40% of the market share.

Read the full market overview

The Asia-Pacific region is the world's largest market, with a market share of about 45%, followed by North America with nearly 20%

This report provides an overview of the global Drugs for Vulvovaginal Candidiasis market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Drugs for Vulvovaginal Candidiasis and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Drugs for Vulvovaginal Candidiasis sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Drugs for Vulvovaginal Candidiasis market size, projected growth trends, production technologies, key applications, and end-use industries.

Drugs for Vulvovaginal Candidiasis Segment by Company

Bayer

Perrigo

J & J

Pfizer

Bristol-Myers Squibb

Effik

Teva

Sanofi

Cisen Pharmaceutical

Kingyork Group

Drugs for Vulvovaginal Candidiasis Segment by Type

Cream

Pessary

Other

Drugs for Vulvovaginal Candidiasis Segment by Application

Hospital & Clinic

Pharmacy

Drugs for Vulvovaginal Candidiasis Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Drugs for Vulvovaginal Candidiasis market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Drugs for Vulvovaginal Candidiasis and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Drugs for Vulvovaginal Candidiasis.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Drugs for Vulvovaginal Candidiasis market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Drugs for Vulvovaginal Candidiasis manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Drugs for Vulvovaginal Candidiasis in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Drugs for Vulvovaginal Candidiasis in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Drugs for Vulvovaginal Candidiasis Industry Trends Table 2. Drugs for Vulvovaginal Candidiasis Industry Drivers Table 3. Drugs for Vulvovaginal Candidiasis Industry Opportunities and Challenges Table 4. Drugs for Vulvovaginal Candidiasis Industry Restraints Table 5. Global Drugs for Vulvovaginal Candidiasis Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Drugs for Vulvovaginal Candidiasis Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Drugs for Vulvovaginal Candidiasis Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Manufacturers Table 9. Global Drugs for Vulvovaginal Candidiasis Average Sales Price (USD/Unit) of Manufacturers (2021-2026) Table 10. Global Drugs for Vulvovaginal Candidiasis Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Drugs for Vulvovaginal Candidiasis Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Drugs for Vulvovaginal Candidiasis Manufacturers, Product Type & Application Table 13. Global Drugs for Vulvovaginal Candidiasis Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Drugs for Vulvovaginal Candidiasis by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Cream Table 17. Major Manufacturers of Pessary Table 18. Major Manufacturers of Other Table 19. Global Drugs for Vulvovaginal Candidiasis Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global Drugs for Vulvovaginal Candidiasis Sales by Type (2021-2026) & (K Units) Table 21. Global Drugs for Vulvovaginal Candidiasis Sales by Type (2027-2032) & (K Units) Table 22. Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Type (2021-2026) Table 23. Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Type (2027-2032) Table 24. Global Drugs for Vulvovaginal Candidiasis Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 25. Global Drugs for Vulvovaginal Candidiasis Revenue by Type (2021-2026) & (K Units) Table 26. Global Drugs for Vulvovaginal Candidiasis Revenue by Type (2027-2032) & (K Units) Table 27. Global Drugs for Vulvovaginal Candidiasis Revenue Market Share by Type (2021-2026) Table 28. Global Drugs for Vulvovaginal Candidiasis Revenue Market Share by Type (2027-2032) Table 29. Major Manufacturers of Hospital & Clinic Table 30. Major Manufacturers of Pharmacy Table 31. Global Drugs for Vulvovaginal Candidiasis Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 32. Global Drugs for Vulvovaginal Candidiasis Sales by Application (2021-2026) & (K Units) Table 33. Global Drugs for Vulvovaginal Candidiasis Sales by Application (2027-2032) & (K Units) Table 34. Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Application (2021-2026) Table 35. Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Application (2027-2032) Table 36. Global Drugs for Vulvovaginal Candidiasis Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 37. Global Drugs for Vulvovaginal Candidiasis Revenue by Application (2021-2026) & (K Units) Table 38. Global Drugs for Vulvovaginal Candidiasis Revenue by Application (2027-2032) & (K Units) Table 39. Global Drugs for Vulvovaginal Candidiasis Revenue Market Share by Application (2021-2026) Table 40. Global Drugs for Vulvovaginal Candidiasis Revenue Market Share by Application (2027-2032) Table 41. Global Drugs for Vulvovaginal Candidiasis Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 42. Global Drugs for Vulvovaginal Candidiasis Sales by Region (2021-2026) & (K Units) Table 43. Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Region (2021-2026) Table 44. Global Drugs for Vulvovaginal Candidiasis Sales Forecasted by Region (2027-2032) & (K Units) Table 45. Global Drugs for Vulvovaginal Candidiasis Sales Forecasted Market Share by Region (2027-2032) Table 46. North America Drugs for Vulvovaginal Candidiasis Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 47. North America Drugs for Vulvovaginal Candidiasis Sales by Country (2021-2026) & (K Units) Table 48. North America Drugs for Vulvovaginal Candidiasis Sales by Country (2027-2032) & (K Units) Table 49. Europe Drugs for Vulvovaginal Candidiasis Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 50. Europe Drugs for Vulvovaginal Candidiasis Sales by Country (2021-2026) & (K Units) Table 51. Europe Drugs for Vulvovaginal Candidiasis Sales by Country (2027-2032) & (K Units) Table 52. Asia Pacific Drugs for Vulvovaginal Candidiasis Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 53. Asia Pacific Drugs for Vulvovaginal Candidiasis Sales by Country (2021-2026) & (K Units) Table 54. Asia Pacific Drugs for Vulvovaginal Candidiasis Sales by Country (2027-2032) & (K Units) Table 55. South America, Middle East and Africa Drugs for Vulvovaginal Candidiasis Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 56. South America, Middle East and Africa Drugs for Vulvovaginal Candidiasis Sales by Country (2021-2026) & (K Units) Table 57. South America, Middle East and Africa Drugs for Vulvovaginal Candidiasis Sales by Country (2027-2032) & (K Units) Table 58. Global Drugs for Vulvovaginal Candidiasis Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global Drugs for Vulvovaginal Candidiasis Revenue by Region (2021-2026) & (US$ Million) Table 60. Global Drugs for Vulvovaginal Candidiasis Revenue by Region (2027-2032) & (US$ Million) Table 61. Global Drugs for Vulvovaginal Candidiasis Revenue Market Share by Region (2021-2026) Table 62. Global Drugs for Vulvovaginal Candidiasis Revenue Market Share by Region (2027-2032) Table 63. Bayer Company Information Table 64. Bayer Business Overview Table 65. Bayer Drugs for Vulvovaginal Candidiasis Sales (K Units), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. Bayer Drugs for Vulvovaginal Candidiasis Product Portfolio Table 67. Bayer Recent Development Table 68. Perrigo Company Information Table 69. Perrigo Business Overview Table 70. Perrigo Drugs for Vulvovaginal Candidiasis Sales (K Units), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Perrigo Drugs for Vulvovaginal Candidiasis Product Portfolio Table 72. Perrigo Recent Development Table 73. J & J Company Information Table 74. J & J Business Overview Table 75. J & J Drugs for Vulvovaginal Candidiasis Sales (K Units), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. J & J Drugs for Vulvovaginal Candidiasis Product Portfolio Table 77. J & J Recent Development Table 78. Pfizer Company Information Table 79. Pfizer Business Overview Table 80. Pfizer Drugs for Vulvovaginal Candidiasis Sales (K Units), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. Pfizer Drugs for Vulvovaginal Candidiasis Product Portfolio Table 82. Pfizer Recent Development Table 83. Bristol-Myers Squibb Company Information Table 84. Bristol-Myers Squibb Business Overview Table 85. Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Sales (K Units), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Product Portfolio Table 87. Bristol-Myers Squibb Recent Development Table 88. Effik Company Information Table 89. Effik Business Overview Table 90. Effik Drugs for Vulvovaginal Candidiasis Sales (K Units), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 91. Effik Drugs for Vulvovaginal Candidiasis Product Portfolio Table 92. Effik Recent Development Table 93. Teva Company Information Table 94. Teva Business Overview Table 95. Teva Drugs for Vulvovaginal Candidiasis Sales (K Units), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 96. Teva Drugs for Vulvovaginal Candidiasis Product Portfolio Table 97. Teva Recent Development Table 98. Sanofi Company Information Table 99. Sanofi Business Overview Table 100. Sanofi Drugs for Vulvovaginal Candidiasis Sales (K Units), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 101. Sanofi Drugs for Vulvovaginal Candidiasis Product Portfolio Table 102. Sanofi Recent Development Table 103. Cisen Pharmaceutical Company Information Table 104. Cisen Pharmaceutical Business Overview Table 105. Cisen Pharmaceutical Drugs for Vulvovaginal Candidiasis Sales (K Units), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 106. Cisen Pharmaceutical Drugs for Vulvovaginal Candidiasis Product Portfolio Table 107. Cisen Pharmaceutical Recent Development Table 108. Kingyork Group Company Information Table 109. Kingyork Group Business Overview Table 110. Kingyork Group Drugs for Vulvovaginal Candidiasis Sales (K Units), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 111. Kingyork Group Drugs for Vulvovaginal Candidiasis Product Portfolio Table 112. Kingyork Group Recent Development Table 113. Key Raw Materials Table 114. Raw Materials Key Suppliers Table 115. Drugs for Vulvovaginal Candidiasis Distributors List Table 116. Drugs for Vulvovaginal Candidiasis Customers List Table 117. Research Programs/Design for This Report Table 118. Authors List of This Report Table 119. Secondary Sources Table 120. Primary Sources List of Figures Figure 1. Drugs for Vulvovaginal Candidiasis Product Image Figure 2. Global Drugs for Vulvovaginal Candidiasis Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Drugs for Vulvovaginal Candidiasis Market Size (2021-2032) & (US$ Million) Figure 4. Global Drugs for Vulvovaginal Candidiasis Sales (2021-2032) & (K Units) Figure 5. Global Drugs for Vulvovaginal Candidiasis Average Price (USD/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Drugs for Vulvovaginal Candidiasis Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Cream Image Figure 9. Pessary Image Figure 10. Other Image Figure 11. Global Drugs for Vulvovaginal Candidiasis Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global Drugs for Vulvovaginal Candidiasis Sales Market Share 2021 VS 2025 VS 2032 Figure 13. Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Type (2021-2032) Figure 14. Global Drugs for Vulvovaginal Candidiasis Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 15. Global Drugs for Vulvovaginal Candidiasis Revenue Market Share 2021 VS 2025 VS 2032 Figure 16. Global Drugs for Vulvovaginal Candidiasis Revenue Market Share by Type (2021-2032) Figure 17. Hospital & Clinic Image Figure 18. Pharmacy Image Figure 19. Global Drugs for Vulvovaginal Candidiasis Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 20. Global Drugs for Vulvovaginal Candidiasis Sales Market Share 2021 VS 2025 VS 2032 Figure 21. Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Application (2021-2032) Figure 22. Global Drugs for Vulvovaginal Candidiasis Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 23. Global Drugs for Vulvovaginal Candidiasis Revenue Market Share 2021 VS 2025 VS 2032 Figure 24. Global Drugs for Vulvovaginal Candidiasis Revenue Market Share by Application (2021-2032) Figure 25. North America Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2021-2032) & (K Units) Figure 26. North America Drugs for Vulvovaginal Candidiasis Sales Market Share by Country (2021-2032) Figure 27. U.S. Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2021-2032) & (K Units) Figure 28. Canada Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2021-2032) & (K Units) Figure 29. Mexico Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2021-2032) & (K Units) Figure 30. Europe Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Europe Drugs for Vulvovaginal Candidiasis Sales Market Share by Country (2021-2032) Figure 32. Germany Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2021-2032) & (K Units) Figure 33. France Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2021-2032) & (K Units) Figure 34. U.K. Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2021-2032) & (K Units) Figure 35. Italy Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2021-2032) & (K Units) Figure 36. Netherlands Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2021-2032) & (K Units) Figure 37. Asia Pacific Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Asia Pacific Drugs for Vulvovaginal Candidiasis Sales Market Share by Country (2021-2032) Figure 39. China Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Japan Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2021-2032) & (K Units) Figure 41. South Korea Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2021-2032) & (K Units) Figure 42. Southeast Asia Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2021-2032) & (K Units) Figure 43. India Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2021-2032) & (K Units) Figure 44. Australia Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2021-2032) & (K Units) Figure 45. South America, Middle East and Africa Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2021-2032) & (K Units) Figure 46. South America, Middle East and Africa Drugs for Vulvovaginal Candidiasis Sales Market Share by Country (2021-2032) Figure 47. Brazil Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2021-2032) & (K Units) Figure 48. South Africa Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2021-2032) & (K Units) Figure 49. Saudi Arabia Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2021-2032) & (K Units) Figure 50. Turkey Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2021-2032) & (K Units) Figure 51. Argentina Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2021-2032) & (K Units) Figure 52. UAE Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Egypt Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Chile Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Global Drugs for Vulvovaginal Candidiasis Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Global Drugs for Vulvovaginal Candidiasis Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 57. North America Drugs for Vulvovaginal Candidiasis Revenue (2021-2032) & (US$ Million) Figure 58. North America Drugs for Vulvovaginal Candidiasis Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 59. Europe Drugs for Vulvovaginal Candidiasis Revenue (2021-2032) & (US$ Million) Figure 60. Europe Drugs for Vulvovaginal Candidiasis Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Asia-Pacific Drugs for Vulvovaginal Candidiasis Revenue (2021-2032) & (US$ Million) Figure 62. Asia-Pacific Drugs for Vulvovaginal Candidiasis Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. South America, Middle East and Africa Drugs for Vulvovaginal Candidiasis Revenue (2021-2032) & (US$ Million) Figure 64. South America, Middle East and Africa Drugs for Vulvovaginal Candidiasis Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. Drugs for Vulvovaginal Candidiasis Value Chain Figure 66. Manufacturing Cost Structure Figure 67. Drugs for Vulvovaginal Candidiasis Production Mode & Process Figure 68. Direct Comparison with Distribution Share Figure 69. Distributors Profiles Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • Cream
  • Pessary
  • Other
Applications
  • Hospital & Clinic
  • Pharmacy
Companies covered
  • Bayer
  • Perrigo
  • J & J
  • Pfizer
  • Bristol-Myers Squibb
  • Effik
  • Teva
  • Sanofi
  • Cisen Pharmaceutical
  • Kingyork Group

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Drugs for Vulvovaginal Candidiasis Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Drugs for Vulvovaginal Candidiasis Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Drugs for Vulvovaginal Candidiasis Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Drugs for Vulvovaginal Candidiasis Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Drugs for Vulvovaginal Candidiasis Market Dynamics
  1. 2.1 Drugs for Vulvovaginal Candidiasis Industry Trends
  2. 2.2 Drugs for Vulvovaginal Candidiasis Industry Drivers
  3. 2.3 Drugs for Vulvovaginal Candidiasis Industry Opportunities and Challenges
  4. 2.4 Drugs for Vulvovaginal Candidiasis Industry Restraints
3 Drugs for Vulvovaginal Candidiasis Market by Manufacturers
  1. 3.1 Global Drugs for Vulvovaginal Candidiasis Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Drugs for Vulvovaginal Candidiasis Sales by Manufacturers (2021-2026)
  3. 3.3 Global Drugs for Vulvovaginal Candidiasis Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Drugs for Vulvovaginal Candidiasis Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Drugs for Vulvovaginal Candidiasis Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Drugs for Vulvovaginal Candidiasis Manufacturers, Product Type & Application
  7. 3.7 Global Drugs for Vulvovaginal Candidiasis Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Drugs for Vulvovaginal Candidiasis Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Drugs for Vulvovaginal Candidiasis Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Drugs for Vulvovaginal Candidiasis Tier 1, Tier 2, and Tier 3
4 Drugs for Vulvovaginal Candidiasis Market by Type
  1. 4.1 Drugs for Vulvovaginal Candidiasis Type Introduction
  2. 4.1.1 Cream
  3. 4.1.2 Pessary
  4. 4.1.3 Other
  5. 4.2 Global Drugs for Vulvovaginal Candidiasis Sales by Type
  6. 4.2.1 Global Drugs for Vulvovaginal Candidiasis Sales by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Drugs for Vulvovaginal Candidiasis Sales by Type (2021-2032)
  8. 4.2.3 Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Type (2021-2032)
  9. 4.3 Global Drugs for Vulvovaginal Candidiasis Revenue by Type
  10. 4.3.1 Global Drugs for Vulvovaginal Candidiasis Revenue by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Drugs for Vulvovaginal Candidiasis Revenue by Type (2021-2032)
  12. 4.3.3 Global Drugs for Vulvovaginal Candidiasis Revenue Market Share by Type (2021-2032)
5 Drugs for Vulvovaginal Candidiasis Market by Application
  1. 5.1 Drugs for Vulvovaginal Candidiasis Application Introduction
  2. 5.1.1 Hospital & Clinic
  3. 5.1.2 Pharmacy
  4. 5.2 Global Drugs for Vulvovaginal Candidiasis Sales by Application
  5. 5.2.1 Global Drugs for Vulvovaginal Candidiasis Sales by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Drugs for Vulvovaginal Candidiasis Sales by Application (2021-2032)
  7. 5.2.3 Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Application (2021-2032)
  8. 5.3 Global Drugs for Vulvovaginal Candidiasis Revenue by Application
  9. 5.3.1 Global Drugs for Vulvovaginal Candidiasis Revenue by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Drugs for Vulvovaginal Candidiasis Revenue by Application (2021-2032)
  11. 5.3.3 Global Drugs for Vulvovaginal Candidiasis Revenue Market Share by Application (2021-2032)
6 Global Drugs for Vulvovaginal Candidiasis Sales by Region
  1. 6.1 Global Drugs for Vulvovaginal Candidiasis Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Drugs for Vulvovaginal Candidiasis Sales by Region (2021-2032)
  3. 6.2.1 Global Drugs for Vulvovaginal Candidiasis Sales by Region (2021-2026)
  4. 6.2.2 Global Drugs for Vulvovaginal Candidiasis Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Drugs for Vulvovaginal Candidiasis Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Drugs for Vulvovaginal Candidiasis Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Drugs for Vulvovaginal Candidiasis Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Drugs for Vulvovaginal Candidiasis Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Drugs for Vulvovaginal Candidiasis Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Drugs for Vulvovaginal Candidiasis Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Drugs for Vulvovaginal Candidiasis Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Drugs for Vulvovaginal Candidiasis Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Drugs for Vulvovaginal Candidiasis Revenue by Region
  1. 7.1 Global Drugs for Vulvovaginal Candidiasis Revenue by Region
  2. 7.1.1 Global Drugs for Vulvovaginal Candidiasis Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Drugs for Vulvovaginal Candidiasis Revenue by Region (2021-2026)
  4. 7.1.3 Global Drugs for Vulvovaginal Candidiasis Revenue by Region (2027-2032)
  5. 7.1.4 Global Drugs for Vulvovaginal Candidiasis Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Drugs for Vulvovaginal Candidiasis Revenue (2021-2032)
  8. 7.2.2 North America Drugs for Vulvovaginal Candidiasis Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Drugs for Vulvovaginal Candidiasis Revenue (2021-2032)
  11. 7.3.2 Europe Drugs for Vulvovaginal Candidiasis Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Drugs for Vulvovaginal Candidiasis Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Drugs for Vulvovaginal Candidiasis Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Drugs for Vulvovaginal Candidiasis Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Drugs for Vulvovaginal Candidiasis Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Bayer
  2. 8.1.1 Bayer Company Information
  3. 8.1.2 Bayer Business Overview
  4. 8.1.3 Bayer Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Bayer Drugs for Vulvovaginal Candidiasis Product Portfolio
  6. 8.1.5 Bayer Recent Developments
  7. 8.2 Perrigo
  8. 8.2.1 Perrigo Company Information
  9. 8.2.2 Perrigo Business Overview
  10. 8.2.3 Perrigo Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Perrigo Drugs for Vulvovaginal Candidiasis Product Portfolio
  12. 8.2.5 Perrigo Recent Developments
  13. 8.3 J & J
  14. 8.3.1 J & J Company Information
  15. 8.3.2 J & J Business Overview
  16. 8.3.3 J & J Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 J & J Drugs for Vulvovaginal Candidiasis Product Portfolio
  18. 8.3.5 J & J Recent Developments
  19. 8.4 Pfizer
  20. 8.4.1 Pfizer Company Information
  21. 8.4.2 Pfizer Business Overview
  22. 8.4.3 Pfizer Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Pfizer Drugs for Vulvovaginal Candidiasis Product Portfolio
  24. 8.4.5 Pfizer Recent Developments
  25. 8.5 Bristol-Myers Squibb
  26. 8.5.1 Bristol-Myers Squibb Company Information
  27. 8.5.2 Bristol-Myers Squibb Business Overview
  28. 8.5.3 Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Product Portfolio
  30. 8.5.5 Bristol-Myers Squibb Recent Developments
  31. 8.6 Effik
  32. 8.6.1 Effik Company Information
  33. 8.6.2 Effik Business Overview
  34. 8.6.3 Effik Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Effik Drugs for Vulvovaginal Candidiasis Product Portfolio
  36. 8.6.5 Effik Recent Developments
  37. 8.7 Teva
  38. 8.7.1 Teva Company Information
  39. 8.7.2 Teva Business Overview
  40. 8.7.3 Teva Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Teva Drugs for Vulvovaginal Candidiasis Product Portfolio
  42. 8.7.5 Teva Recent Developments
  43. 8.8 Sanofi
  44. 8.8.1 Sanofi Company Information
  45. 8.8.2 Sanofi Business Overview
  46. 8.8.3 Sanofi Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Sanofi Drugs for Vulvovaginal Candidiasis Product Portfolio
  48. 8.8.5 Sanofi Recent Developments
  49. 8.9 Cisen Pharmaceutical
  50. 8.9.1 Cisen Pharmaceutical Company Information
  51. 8.9.2 Cisen Pharmaceutical Business Overview
  52. 8.9.3 Cisen Pharmaceutical Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Cisen Pharmaceutical Drugs for Vulvovaginal Candidiasis Product Portfolio
  54. 8.9.5 Cisen Pharmaceutical Recent Developments
  55. 8.10 Kingyork Group
  56. 8.10.1 Kingyork Group Company Information
  57. 8.10.2 Kingyork Group Business Overview
  58. 8.10.3 Kingyork Group Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Kingyork Group Drugs for Vulvovaginal Candidiasis Product Portfolio
  60. 8.10.5 Kingyork Group Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Drugs for Vulvovaginal Candidiasis Value Chain Analysis
  2. 9.1.1 Drugs for Vulvovaginal Candidiasis Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Drugs for Vulvovaginal Candidiasis Production Mode & Process
  6. 9.2 Drugs for Vulvovaginal Candidiasis Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Drugs for Vulvovaginal Candidiasis Distributors
  9. 9.2.3 Drugs for Vulvovaginal Candidiasis Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst